Click here for slides on this topic


Omega-3 fatty acids

Lipid-lowering agents; also called n-3 fatty acids.
The following content matched the glossary term: Omega-3 fatty acids

AACE 2015 guidelines Cardiovascular Disease Management

Top

Summary of recommendations for managing cardiovascular disease (CVD), including dyslipidemia and hypertension, from the 2015 AACE diabetes guidelines 

American Diabetes Association (ADA) Nutrition Guidelines for Adults With Diabetes

Top

Diabetes management guidelines for nutrition from the American Diabetes Association (ADA)

Clinical Insights in Diabetes Newsletter July 2013

Top

Clinical Insights® in Diabetes newsletter July 2013

Carotid intima-media thickness (CIMT) change in ORIGIN-GRACE, effects of omega-3 fatty acids on CV events in the Risk and Prevention Study, canagliflozin therapy in CANTATA-D2 and CANTATA-M, weight gain and intensive therapy in ACCORD, glycemic control with single daily basal insulin plus corrective glulisine and basal bolus regimen, diurnal pattern to insulin action in type 1 diabetes.

American Heart Association (AHA) Scientific Sessions 2012

Top

Exclusive coverage of late-breaking data from the American Heart Association Scientific Sessions, November 3-7, 2012 in Los Angeles, California are featured in this issue of OnsiteInsight®.

Effect of insulin glargine and n-3FA on carotid intima-media thickness in people with dysglycemia at high risk for cardiovascular events: ORIGIN-GRACE

Top

Lonn EM, Bosch J, Diaz R, et al; for the GRACE and ORIGIN Investigators. Effect of insulin glargine and n-3FA on carotid intima-media thickness in people with dysglycemia at high risk for cardiovascular events: the Glucose Reduction and Atherosclerosis Continuing Evaluation Study (ORIGIN-GRACE). Diabetes Care. 2013;36(9):2466-2474. Findings from ORIGIN-GRACE showed no difference in annualized change in maximum carotid intima-media thickness for 12 carotid artery segments with insulin glargine or omega-3 fatty acid.

n-3 fatty acids in patients with multiple cardiovascular risk factors

Top

The Risk and Prevention Study Collaborative Group. n-3 fatty acids in patients with multiple cardiovascular risk factors. N Engl J Med. 2013;368(19):1800-1808. Results from the Risk and Prevention Study showed no effect of omega-3 fatty acids on cardiovascular (CV) events and mortality among subjects at high CV risk.

OnsiteInsight November 2012

Top

The latest diabetes literature exploring diabetes guidelines, diabetes treatment, diabetes management, and diabetes prevention with commentary from diabetes experts.

NDEI.org Press Release Vivian Fonseca, MD, on “Futility of Adding Omega-3 Fatty Acids in the Hope of Added Benefit” in the ORIGIN Trial

Top

Vivian Fonseca, MD, on the "Futility of Adding Omega-3 Fatty Acids in the Hope of Added Benefit" in the ORIGIN Trial July 31, 2012: NDEI.org, the official website of The National Diabetes Education Initiative® (NDEI®), published today a webcast on the results of the ORIGIN trial featuring expert commentary from Vivian A. Fonseca, MD. “These results may help us to education our patients on the futility of adding omega-3 fatty acids in the hope of added benefit, in the absence of data supporting their use,” said Dr Fonseca, a Professor of Medicine and Pharmacology, and Chief of the Section of Endocrinology at Tulane University Health Sciences Center in New Orleans, Louisiana.

Press Room

Top

NDEI.org press releases and news.

1 2 3 Next 

Slide Library Results

Search Results for: Omega-3 fatty acids Slides Found: 40
ORIGIN Glargine Trial: Design
ORIGIN Glargine Trial: Primary and Secondary Outcomes
ORIGIN Glargine Trial: Eligibility Criteria and Trial Profile
ORIGIN Glargine Trial: Baseline Characteristics (1 of 2)
ORIGIN Glargine Trial: Baseline Characteristics (2 of 2)
ORIGIN Glargine Trial: Insulin Use During Trial
ORIGIN Glargine Trial: A1C, FPG During Trial
ORIGIN Glargine Trial: First Coprimary Composite CV Outcome—CV Death, Nonfatal MI, or Nonfatal Stroke
ORIGIN Glargine Trial: Second Coprimary Composite CV Outcome—CV Death, Nonfatal MI, Nonfatal Stroke, Revascularization, or Hospitalized Heart Failure
ORIGIN Glargine Trial: Secondary Outcomes
ORIGIN Glargine Trial: Secondary Outcome—Cancer Incidence
ORIGIN Glargine Trial: Hypoglycemia
ORIGIN Glargine Trial: Weight Change
ORIGIN Glargine Trial: Conclusions
ORIGIN Omega-3 Fatty Acid Trial: Design
ORIGIN Omega-3 Fatty Acid Trial: Primary and Secondary Outcomes
ORIGIN Omega-3 Fatty Acid Trial: Additional Outcomes
ORIGIN Omega-3 Fatty Acid Trial: Eligibility Criteria and Trial Profile
ORIGIN Omega-3 Fatty Acid Trial: Baseline Characteristics (1 of 2)
ORIGIN Omega-3 Fatty Acid Trial: Baseline Characteristics (2 of 2)
ORIGIN Omega-3 Fatty Acid Trial: Primary Outcome—CV Death
ORIGIN Omega-3 Fatty Acid Trial: Secondary Outcomes
ORIGIN Omega-3 Fatty Acid Trial: Mean Change in Lipids
ORIGIN Omega-3 Fatty Acid Trial: Conclusions
ORIGIN: Design
ORIGIN-GRACE: Design
ORIGIN-GRACE: Summary of Findings
Risk and Prevention Study: Design
Risk and Prevention Study: No Effect of Omega-3 Fatty Acids on CV Events, Mortality
Risk and Prevention Study: Secondary Endpoints
ADA Nutrition Guidelines: Dietary Omega-3 Fatty Acids
ACC/AHA Cholesterol Guidelines 2013: Nonstatin Safety Recommendations: Omega-3 Fatty Acids
IDF Type 2 Diabetes Guidelines CVD Risk Reduction Treatment | NDEI
AACE 2015 Diabetes Guidelines Dyslipidemia Treatment PPT | NDEI
Insulin Glargine Neutral on CV Outcomes & Cancer Diabetes ORIGIN | NDEI
Neutral Omega-3 Effect on CV Outcomes in ORIGIN Diabetes | NDEI
Insulin Glargine A1C Reduction Type 2 Diabetes PPT | NDEI
ORIGINALE No Increase in CV Events or Cancer with Insulin Glargine Diabetes | NDEI
ORIGINALE No Effect of Omega-3 Fatty Acids on CV Outcomes | NDEI
ORIGINALE A1C Reduction With Insulin Glargine Type 2 Diabetes | NDEI